Abraxis BioScience (ABBI) Reports Q4 Earnings, Comments on FY07
More News related to ABBI
- Deloitte Names Abraxis BioScience Inc. Fastest Growing Technology Company in Los Angeles Area
- Deloitte Unveils 2008 Technology Fast 500 Ranking
- Abraxis Pharmaceutical Products (ABBI) Receives Two FDA Approvals
- Abraxis BioScience (ABBI) Receives Tentative FDA Approval for Generic Camptosar Injection
- Abraxis BioScience (ABBI) Receives Tentative FDA Approval for Granisetron
More News related to Earnings
- Home BancShares (HOMB) Pre-Announces Q4 and FY08 Results - Below Consensus
- Syms Corp (SYMS) Reports a Q3 Loss of $0.06; Same-Store Sales Decline 6.4%
- Chase Corporation (CCF) Misses Q1 EPS by 15c
- Centennial Communications (CYCL) Misses Q2 EPS by 6c, Comments on Outlook
- SYNNEX (SNX) Reports Q4 EPS of $0.80, Beats by 10c; Guides Q1
Abraxis BioScience, Inc. (NASDAQ: ABBI) reports Q4 EPS of $0.29 (GAAP EPS was $0.18) vs. consensus of $0.16. Revenues were $257.1 million vs. $208.73 million consensus.
For the full year of 2007, Abraxis is providing the following financial guidance estimates, which excludes effects of stock compensation:
APP segment hospital-based product net sales increase mid-teens from prior year with gross margins between 48 percent and 52 percent, excluding product rights amortization associated with the AstraZeneca product purchase; ABRAXANE net sales between $285 million and $305 million; Company-wide R&D expenses between $100 million and $110 million; and Company-wide Selling, General and Administrative expenses, excluding ABRAXANE commissions, between $195 million and $205 million.
Related Categories
EarningsGuidance
Stocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
